All In MedTech

Device Trial Radar · NCT06664788

A Study of ETHIZIA Versus SURGICEL Original in Controlling Soft Tissue Bleeding During Open Surgery

A Prospective, Multicenter, Randomized Clinical Investigation Evaluating the Safety and Efficacy of ETHIZIA™ Versus SURGICEL® Original in Controlling Minimal, Mild, or Moderate Soft Tissue Bleeding During Open Abdominal, Retroperitoneal, Pelvic, Thoracic (Non-cardiac) and Extremity Surgery

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 108 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

108

Actual

Start

Apr 16, 2025

Primary completion

Sep 3, 2026

Study completion Oct 7, 2026

Sponsor

Lead sponsor
Ethicon, Inc.Public (JNJ)
Sponsor type
Industry
First posted
Oct 30, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 22 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this clinical investigation is to evaluate the safety and efficacy of ETHIZIA to control minimal, mild, or moderate soft tissue bleeding during open surgery when compared to SURGICEL Original in the percentage of cases achieving hemostasis at 3 minutes after product application, and without re-bleeding up to 10 minutes after application.

Conditions

  • Hemostasis
  • Hemostatic Techniques

Interventions

  • ETHIZIADevice

    ETHIZIA patch will be applied to bleeding site intraoperatively.

  • SURGICEL OriginalDevice

    SURGICEL Original will be applied to bleeding site intraoperatively.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Cases Achieving Hemostasis at Three Minutes Following Product Application And With No Rebleeding Up to 10 Minutes Following Application at The Target Bleeding SiteTime frame: Intraoperative (up to 10 minutes)

Locations

7 sites in 2 countries. Site status is shown where the registry gives one.

  • Keck Hospital of USC

    Los Angeles, California

  • Washington University Barnes Jewish Hospital

    St Louis, Missouri

  • Capital Health Medical Center - Hopewell

    Pennington, New Jersey

4 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.